BPTH (Bio-Path Holdings) Forward Dividend Yield %: 0.00% (As of Jun. 25, 2026)


What is Bio-Path Holdings Forward Dividend Yield %?

Bio-Path Holdings BPTH +21.43% Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. The stock has 1 warning sign investors should review. Among 146 Biotechnology companies, Bio-Path Holdings ranks worse than 684930.82% on this metric.

As of today (2026-06-25), the Forward Annual Dividend Yield of Bio-Path Holdings is 0.00%.

As of today (2026-06-25), the Trailing Annual Dividend Yield of Bio-Path Holdings is 0.00%.

BPTH's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.495
* Ranked among companies with meaningful Forward Dividend Yield % only.

Bio-Path Holdings's Dividends per Share for the three months ended in Mar. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Bio-Path Holdings  (OTCPK:BPTH) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Bio-Path Holdings Forward Dividend Yield % Related Terms

BPTH vs ADAPY, ZVSA, CLSDQ: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Bio-Path Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Path Holdings Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's Forward Dividend Yield % falls into.


Bio-Path Holdings Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Bio-Path Holdings (BPTH) has a Forward Dividend Yield % of 0.00% as of Jun. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Bio-Path Holdings and its competitors. According to the industry distribution chart, Bio-Path Holdings ranks #999999 out of 146 companies in the Biotechnology industry.
Is Bio-Path Holdings' Forward Dividend Yield % too high?
Bio-Path Holdings' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Bio-Path Holdings ranks #999999 out of 146 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Path Holdings' Forward Dividend Yield % compare to ADAPY and ZVSA?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #999999 out of 146 companies for Forward Dividend Yield %. This places Bio-Path Holdings in the lower half of its industry. The industry median Forward Dividend Yield % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.50, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Bio-Path Holdings and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Path Holdings's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.